or Try an Advanced Search...

    Hemophilia A Stocks List

    Symbol Grade Name % Change
    BAX C Baxter International Inc. -0.25
    CNTA D Centessa Pharmaceuticals plc -0.11
    SGMO F Sangamo BioSciences, Inc. 2.94
    ALNY F Alnylam Pharmaceuticals, Inc. -0.28
    View As Page of Charts
    Related Industries: Biotechnology Medical Instruments & Supplies
    Related Stock Lists: Hemophilia Alpha 1 Antitrypsin Antitrypsin Deficiency Biotechnology Deficiency Hemoglobin Hemoglobinopathies Huntington's Disease Life Sciences Treatment Of Hemophilia Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Autosomal Dominant Polycystic Kidney Disease Beta Thalassemia Biopharmaceutical Biosurgery Products Blastoma

    Related ETFs - A few ETFs which own one or more of the above listed Hemophilia A stocks.

    Symbol Grade Name Weight
    GERM D ETFMG Treatments Testing and Advancements ETF 6.36
    BTEC C Principal Healthcare Innovators Index ETF 3.32
    GNOM F Global X Genomics & Biotechnology ETF 3.31
    FBT D First Trust Amex Biotech Index Fund 3.3
    IHI C iShares U.S. Medical Devices ETF 2.61
    View all Hemophilia A ETFs...
    Compare ETFs
    Compare BTEC to FBT Compare BTEC to IHI Compare GNOM to IHI

        Hemophilia A Stocks Recent News

        Date Stock Title
        Apr 25 BAX ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
        Apr 24 CNTA Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
        Apr 24 CNTA Centessa Pharmaceuticals prices $100M ADS offering
        Apr 24 CNTA Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
        Apr 23 CNTA Centessa Pharmaceuticals announces $100M proposed public offering of American Depositary Shares
        Apr 23 CNTA Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
        Apr 22 SGMO Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
        Apr 22 CNTA Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
        Related Industries: Biotechnology Medical Instruments & Supplies
        Related Stock Lists: Hemophilia Alpha 1 Antitrypsin Antitrypsin Deficiency Biotechnology Deficiency Hemoglobin Hemoglobinopathies Huntington's Disease Life Sciences Treatment Of Hemophilia Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Autosomal Dominant Polycystic Kidney Disease Beta Thalassemia Biopharmaceutical Biosurgery Products Blastoma
        Hemophilia A

        Haemophilia A (or hemophilia A) is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males. In the majority of cases it is inherited as an X-linked recessive trait, though there are cases which arise from spontaneous mutations.Factor VIII medication may be used to treat and prevent bleeding in people with haemophilia A.

        More about Hemophilia A
        Browse All Tags